Physician profile
Christopher Buchanan
NPI 1972076073
$999.77
in general payments reported to CMS, 2019-2025
15 companies · $481 in 2025
The $481 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $153 · 2024: $366 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $202.34 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $158.69 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $134.74 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $111.20 | 2024-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $90.19 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $53.13 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $45.51 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $44.09 | 2023-2025 | Rexulti |
| Esperion Therapeutics, INC. | $28.96 | 2023-2024 | Nexletol |
| Dexcom, INC. | $25.35 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $24.21 | 2025 | Fluad, Flucelvax |
| Vertex Pharmaceuticals Incorporated | $24.02 | 2025 | |
| Medtronic, INC. | $22.15 | 2024 | Interstim |
| Boston Scientific Corporation | $18.19 | 2025 | Epic Biliary |
| Astrazeneca Pharmaceuticals Lp | $17.00 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.